Bortezomib (Velcade, PS341) was licensed in 2003 as a first-in-class 20S proteasome inhibitor indicated for treatment of multiple myeloma, and is currently being evaluated clinically in a range of solid tumours. The mechanisms underlying its cancer cell toxicity are complex. A growing body of evidence suggests proteasome inhibition-dependent regulation of the BCL-2 family is a critical requirement. In particular, the stabilization of BH3-only proteins BIK, NOXA and BIM, appear to be essential for effecting BAX-and BAK-dependent cell death. These mechanisms are reviewed and the implications for favourable novel drug interactions are highlighted.
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Oncogene ( 
Proteasome regulation by polyubiquitination
The ubiquitin-proteasome pathway was originally identified in 1984 as the principal cellular pathway responsible for the fast and specific degradation of short-lived proteins, and has been validated in recent years as a novel target for anticancer therapy Finley et al., 1984) . Ubiquitin ligases are one of the largest family of enzymes and specifically mark proteins for destruction with a polymer of ubiquitin, a 9-kDa 76-amino-acid peptide. The 26S proteasome is a 2 MDa multimeric cylindrical complex comprising a 20S catalytic core and a 19S regulatory subunit. The core is involved in degradation of proteins into small peptides of less than 25 amino acids (Nussbaum et al., 1998) , and is composed of two central b-rings (comprising seven subunits) sandwiched by two a-rings. Proteolysis occurs at the b-rings that exhibit three enzyme activities: trypsin-like (T-L), chymotrypsin-like (CT-L) and caspase-like (C-L) ( Figure 1a ).
Ubiquitin-dependent proteolysis is required for ensuring normal cellular function, in particular, regulation of cellular proliferation and apoptosis (Pagano and Benmaamar, 2003) . Mutations leading to abnormalities of the ubiquitin-proteasome pathway directly affect the function of proteins controlling cell growth and death (Latif et al., 1993; Jaakkola et al., 2001) . Bortezomib (Velcade, PS-341) was identified as a potent dipeptide boronic acid and chymotryptic site-selective inhibitor in an NCI 60 cell line screen and was the first-in-class to receive Federal Drug Administration approval in 2003 for the treatment of multiple myeloma (Bross et al., 2004) . Several clinical trials are currently ongoing in a wide range of solid malignancies. Bortezomib reversibly inhibits the 20S proteasome (K i 0.6 nM) by targeting a threonine residue on the CT-L subunit. 20S antagonism is also associated with inhibition of C-L and T-L activities (Chauhan et al., 2005) . Bortezomib exhibits tumour-selective toxicity. This is despite inhibiting the 20S proteasome in healthy cells, suggesting differential susceptibility of malignant compared with normal cells to proteasome inhibition LeBlanc et al., 2002) . The immediate downstream consequences of inhibiting the 20S activity are complex and are dependent on the phenotype, for example, p53 expression MacLaren et al., 2001) . G 2 -M arrest is correlated with elevation of the cyclin-dependent kinase inhibitors p21, p27, p16, p18 and p19 Ling et al., 2003a; Coquelle et al., 2006) . Inhibition of nuclear factor-kB (NF-kB) has been implicated in the mechanism of toxicity of bortezomib Fahy et al., 2005) . Proteasomal degradation of inhibitory-kB (IkB) enables NF-kB release, its nuclear translocation and function as a transcriptional activator of antiapoptotic oncogenes including BCL-X L and A1 (Zabel and Baeuerle, 1990; Anan et al., 2006) . Inhibition of IkB proteolysis by bortezomib, however, does not underpin toxicity, since it is a much more potent apoptosis inducer compared with the specific IkB inhibitor, PS-1145 (Hideshima et al., 2001) . A growing body of evidence points to the regulation of mitochondria, the cell's pivotal regulators of apoptosis and integrating centres for diverse death signals, as the primary target for damage by bortezomib (Ling et al., 2003b) . Furthermore, the key activators of mitochondrial apoptosis, the BCL-2 family, play a fundamental role in mediating its toxicity (Figure 1b ).
BAX and BAK are activated by bortezomib
Mitochondrial outer membrane permeabilization or MOMP is an essentially irreversible point of commitment to apoptosis associated with release of intermembrane space proapoptotic proteins such as cytochrome c, SMAC, OMI, AIF and endonuclease G (McCurrach et al., 1997; Susin et al., 1999; Chai et al., 2000; Wei et al., 2001; Hegde et al., 2002; Martins et al., 2002; Arnoult et al., 2003) . MOMP requires activation of the multidomain proapoptotic BCL-2 family members BAX and BAK (Oltvai et al., 1993; Boyd et al., 1995) , homologous tumour suppressors and essential determinants of sensitivity to anticancer chemotherapy (Yin et al., 1997; Du et al., 2000; Wei et al., 2001) . BAX typically resides in the cytoplasm or loosely attached to mitochondrial, endoplasmic reticulum (ER) or nuclear membranes, whereas BAK is constitutively resident in the outer mitochondrial membrane (OMM). During activation, BAX, which exhibits structural similarity to the T domain of diphtheria toxin, undergoes a conformation change leading to exposure of the N terminus and C-terminal mitochondrial addressing domain to allow OMM docking (Wolter et al., 1997; Goping et al., 1998) and deep membrane insertion.
BAX and BAK are activated by a subfamily of BCL-2 family proteins that share the third BCL-2 homology (BH3) domain. They have been previously divided into two subclasses. The 'activator' class is represented by BID, BIM and possibly PUMA, which can directly promote conformation change in BAX and BAK (Wang et al., 1996) . Critical residues in the first a-helical domain have been identified as essential for BAX agonism (Cartron et al., 2004; Kim et al., 2006) . The sensitizer subclass of BH3-only proteins include the p53-inducible protein NOXA (Oda et al., 2000; Shibue et al., 2003) , BIK (Cheng et al., 1996) , BMF, BAD, HRK and BNIP3 (Yang et al., 1995; Inohara et al., 1997; Yasuda et al., 1999; Puthalakath et al., 2001) . These proteins regulate the interaction between proapoptotic and antiapoptotic BCL-2 family members via heterodimerization with antiapoptotic BCL-2 family members (Kim et al., 2006) such that their displacement enables full BAX and BAK activation to occur. Recent evidence proposes a model in which all BH3 proteins exhibit sensitizer activity, characterized by their selectivity for antiapoptotic BCL-2 members and release of BAX and BAK (Willis et al., 2007) .
BAX is downregulated by hypoxia in tumour cells; however, this mechanism is related to hypoxia-inducible factor-1a (HIF1a)-dependent reduction in translation rather than proteasome-dependent elimination (Erler et al., 2004) . Although bortezomib has been shown to induce BAX (and BAK) conformation change (PerezGalan et al., 2006) , studies examining the effect of bortezomib on BAX and BAK expression have not identified an increase in level of these proteins that might contribute to its proapoptotic efficacy (Table 1) ; furthermore, neither of the activator BH3-only proteins BID nor PUMA have been shown to be upregulated by bortezomib (Zhu et al., 2005b; Qin et al., 2006) . PUMA has been shown recently, however, to be upregulated in a p53-dependent manner in response to the proteasome inhibitor epoxomicin (epoxo) (Concannon et al., 2007) .
Regulation of the activator BH3 protein BIM by bortezomib
BIM is an intrinsically unstructured BH3-only protein (Hinds et al., 2007) that is constitutively expressed in several tissues and exists as a number of splice variants the first of which were identified as BIM EL (the largest), BIM L and BIM S (the smallest). The latter exhibits the most potent apoptosis-inducing activity (O'Connor et al., 1998; O'Reilly et al., 2000) . BIM is encoded by the BCL-2L2 gene at 2q13 that consists of six exons. Splicing of the third exon results in expression of the smaller isoforms (Bouillet et al., 2001) . Several new isoforms of BIM have been identified including a1-2, b1-4 (Wei et al., 2001 ) and BIM AD (Marani et al., 2002) , and others (Adachi et al., 2005) although BIM EL and BIM L are the most relevant splice variants in vivo. BIM is a tumour suppressor which has been shown to exhibit homozygous deletion in Mantle cell lymphoma (Tagawa et al., 2005) . BIM mRNA stability is inhibited by cytokines that act via HSP70 (acting in concert with RAS transcriptionally regulated co-chaperones Bag-4, CHIP, HIP and HSP40). These bind the 3 0 AU-rich elements of the BIM transcript stabilizing it, in a process that links cytokines to the cell survival machinery (Matsui et al., 2007) .
Inactivation of BIM results from its normal restraint by constitutive interaction with cytoplasmic dynein light chain LC8 linked to the microtubule-associated dynein motor complex (Puthalakath et al., 1999) . Cytokines such as epidermal growth factor in addition to destabilizing BIM mRNA, promotes extracellular signal-regulated kinase-and mitogen-activated protein kinase-mediated phosphorylation of BIM (on serines 55, 65, 69 and 100), inhibiting its interaction with BAX (Harada et al., 2004) and driving its degradation via the proteasome (Ley et al., 2003 (Ley et al., , 2004 Luciano et al., 2003; Reginato et al., 2003; Marani et al., 2004; Annis et al., 2005) . Conversely, loss of survival signals can activate BIM-induced apoptosis (Abrams et al., 2004) . Dissociation from LC8 is a caspase-independent event and is driven by JNK phosphorylation (Lei and Davis, 2003) that leads to translocation of BIM, interaction and activation of BAX/BAK. The p53 and the BRCA1 transcriptionally regulated protein GADD45a mediates apoptosis by dissociating BIM from the cytoskeleton via an interaction with the microtubule-severing protein EF1-a (Tong et al., 2005) . Microtubule damaging agents such as paclitaxel require BIM to induce apoptosis (Sunters et al., 2003; Anderson, 2005; Annis et al., 2005) , as is the case for glucocorticoids (Ling et al., 2003a; Abrams et al., 2004; Zhang and Insel, 2004) . Following release, BIM translocates to ER where it mediates activation of caspase 12 (Morishima et al., 2004) .
Bortezomib reverses mitogen-activated protein kinase pathway-dependent BIM phosphorylation by inhibiting its degradation in the proteasome (Annis et al., 2005; Figure 2a ). Accumulation of BIM is sufficient to restore sensitivity of H-RAS expressing tumours to paclitaxel. Knockout studies in mouse embryonic fibroblasts have demonstrated that loss of BIM together with BIK confers resistance to Bortezomib-induced cytotoxicity (Nikrad et al., 2005) . Resensitization to taxanes by BIM probably explains the previously reported additive, preclinical interactions between bortezomib and paclitaxel in vivo (Teicher et al., 1999; Nawrocki et al., 2004) . However, a recent phase II trial randomizing patients to bortezomib alone or docetaxel and bortezomib, demonstrated only minor evidence of enhancement in clinical outcome (Fanucchi et al., 2006) , suggesting that other determinants of sensitivity or resistance to bortezomib and docetaxel are likely to be relevant in this disease setting. One relevant factor, for example, may be bortezomib-mediated p21-dependent antagonism of docetaxel that has been reported in prostate cancer cells (Canfield et al., 2006) .
Antagonism of MCL-1 by bortezomib
NOXA was originally identified as a p53 transcriptionally regulated BH3-only protein that is expressed following genotoxic damage and localizes to the mitochondrial outer membrane (Oda et al., 2000; Yakovlev et al., 2004) . In the absence of p53, E1A can activate p73-induced expression of NOXA, as can hypoxic stress via a HIF1a-dependent transcriptional mechanism (Kim et al., 2004) . DNA damage-induced cell death is attenuated in NOXA knockout mice (Villunger et al., 2003) , and loss of BAX abrogates NOXA-mediated apoptosis (Shibue et al., 2003) , indeed BAK has been shown to be not required for NOXA-mediated cytochrome c release (Seo et al., 2003) . NOXA exhibits very limited binding specificity to antiapoptotic BCL-2 family members determined by its BH3 domain structure, and preferentially interacts with MCL-1 and A1 (Chen et al., 2005) . Bortezomib increases the expression of NOXA (Fernandez et al., 2005; Perez-Galan et al., 2006) , within a relatively short time frame of 4-6 h, Figure 2b (PerezGalan et al., 2006). Melanoma cells exposed to bortezomib undergo induction of apoptosis to over 50-fold over baseline expression as early as 3 h after treatment, but not in normal keratinocytes (Fernandez et al., 2005) . Upregulation of NOXA has also been observed in adult T-cell leukaemia, breast cancer and non-small cell lung cancer cell lines. This tumourselective upregulation of NOXA is distinct from BIM, which is upregulated in both normal and cancer cells. Expression of NOXA mRNA and protein is induced by bortezomib, and is potentiated by the presence of wildtype p53, but occurs in a p53-independent manner. NOXA mRNA is upregulated between approximately 50-fold in melanoma cells compared to melanocytes consistent with de novo transcription as well as increased protein stability. However, the mechanisms underlying transcriptional regulation are unclear.
Knockdown of NOXA using short-hairpin RNA interference attenuates toxicity by bortezomib (50% reduction in cell death) consistent with its role in mediating apoptosis. Toxicity requires NOXA-dependent generation of reactive oxygen species and is inhibited by free radical scavengers (Perez-Galan et al., 2006) . Systemic administration of bortezomib in vivo increases the expression of NOXA in human melanoma xenografts grown in nude mice with associated reduction in tumor growth.
The involvement of NOXA in bortezomib-mediated apoptosis, implies targeting of MCL-1, a multidomain antiapoptotic protein localized to the OMM, where it interacts with and inhibits BAK and/or BAX. MCL-1 is subject to rapid turnover and short half-life of around 30 min (Adams and Cooper, 2007) . Recent evidence employing global inhibition of translation using a cycloheximide-induced apoptosis model, has shown that loss of MCL-1 is a critical event that leads to activation of BIM, BAX and BAK (Adams and Cooper, 2007) . The solution structure of MCL-1 reveals a homologous structure to other members of the BCL-2 family including a hydrophobic 'receptor-like' groove on the surface involved in BH3 domain sequestration; however, MCL-1 is unique in that the hydrophobic groove is intermediate between the ligand-bound structure, and the closed state of unbound BCL-2 proteins (Chen et al., 2005) . This feature determines the specificity for BH3 domain interaction, and in particular, that of NOXA. BAK is guarded from its activator BH3 proteins by MCL-1 (along with BCL-X L ), which directly sequesters tBID (Clohessy et al., 2006) and BIM (Gomez-Bougie et al., 2005) but also binds BAK directly, inhibiting its activation until released by free BH3-only proteins (Chen et al., 2005) . The binding of tBID by MCL-1 may account for the mechanism underlying its ability to confer resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL; Henson et al., 2003; Taniai et al., 2004; Canfield et al., 2006) . MCL-1 is targeted for polyubiquitination and proteasome-mediated degradation following DNA damage by the BH3-only protein MULE-1/ARF/LASU1 (Nijhawan et al., 2003; Warr et al., 2005; Zhong et al., 2005) . MCL-1 elimination also occurs as a consequence of anoxia (Brunelle et al., 2007) . MULE is a large (480 kDa protein) possessing a BH3 domain that interacts with MCL-1 but is incapable of interaction with BCL-2 or BCL-X L , and comprises a HECT domain with E3 ligase activity (Zhong et al., 2005) . When bound to MCL-1, MULE induces polyubiquitination; however, the MULE-1-MCL-1 interaction is blocked by BH3-only proteins including BID, BIM or PUMA resulting in elevation of MCL-1 level, presumably via prevention of access to E3 ligase activity (Mei et al., 2005; Warr et al., 2005) . A second mechanism underlying proteasomal clearance of MCL-1 is associated with its phosphorylation by the AKT substrate, glycogen synthase kinase 3, on a conserved serine site, S159 (Maurer et al., 2006) . Finally, granzyme B or activation of caspases 3 and 7, for example by TRAIL directly degrades MCL-1 resulting in the disruption of its interaction with BIM, freeing BIM to engage with BAX (Han et al., 2004; Herrant et al., 2004; Annis et al., 2005; Canfield et al., 2006) .
Bortezomib significantly upregulates MCL-1 following treatment (Qin et al., 2005 (Qin et al., , 2006 , and this effect is likely to be due to prolongation of its half-life. Cells in which there is high expression of MCL-1, exhibit resistance to proteasome inhibitors (Nencioni et al., 2005a; Qin et al., 2006) . Conversely, downregulation of MCL-1 expression by ultraviolet light, fludarabine or small interfering RNA against MCL-1, enables bortezomib to induce toxicity in melanoma cells suggesting that a high NOXA/MCL-1 ratio is required for optimal killing by bortezomib (Qin et al., 2006) . Furthermore, this finding suggests that rational strategies to induce the downregulation of MCL-1 including DNA damage, may be effective in promoting NOXA-mediated toxicity and enhancement of bortezomib activity in the clinical setting.
Regulation of BIK-dependent ER-mitochondria signaling by bortezomib BIK (also known as natural born killer or NBK) is an intrinsically unstructured sensitizer BH3-only protein that mediates cytotoxicity through a direct interaction with BCL-2 and BCL-X L (Boyd et al., 1995) , and requires BAX to mediate mitochondrial-dependent apoptosis (Boyd et al., 1995; Cheng et al., 1996; Tong et al., 2001; Gillissen et al., 2003) . BIK expression is lost in renal cell cancer due to methylation-dependent transcriptional silencing of the NBK gene at 22q13.2, which correlates with loss of BIM (Sturm et al., 2006) .
BIK localizes predominantly to the ER as an anchored protein, via its COOH terminal, which crosses the ER membrane. Its expression is induced by genotoxic and oncogenic stress but not the unfolded protein response secondary to ER stress , and it is capable of inducing apoptosis independent of a physical association with the mitochondrial outer membrane Mathai et al., 2002) . BIK releases cytochrome c and activates caspases by directly promoting ER-mitochondria calcium signaling and requires its BH3 domain for activity (Tong et al., 2001) . Calcium depletion from ER stores is induced by BIK overexpression. The mechanism involves BAX and BAK which both translocate and oligomerize in a BIK-dependent manner into the ER membrane. Cells with BAX and BAK double knockout are resistant to BIK-induced calcium release from ER stores ; BAX and BAK mediate uptake of calcium into the ER via a BCL-2 inhibitable interaction with inositol 3-phosphate receptor type 1, and their absence attenuates calcium-mitochondrial signaling Oakes et al., 2005) .
The consequence of ER calcium release is the recruitment of DRP-1 to the OMM, fragmentation of the mitochondrial reticular network (thread-to-grain transition), and sensitization to activators of cytochrome c release Mathai et al., 2005) . Induction of apoptosis by BIK stimulates unfolding of BAX, which is required for apoptosis induction and cannot be substituted by BAK alone (Gillissen et al., 2003) . Bortezomib directly regulates the expression level of BIK, and this is associated with proapoptotic efficacy. Zhu et al. (2005b) have reported that treatment of the lung cancer cell line H1299, the ovarian cancer cell line SKOV3, and the colon cancer cell lines DLD-1, LOVO, SW620 and HCT116 with 100-500 nM bortezomib for 6 h, results in significant upregulation of BIK commencing at 3 h and increasing with time. BIK upregulation is also induced by other proteasome inhibitors such as MG132 or ALLN.
BIK upregulation by bortezomib is not dependent on changes in NF-kB; however, its half-life is dramatically extended from 1 h to over 6 h. Induction of apoptosis by bortezomib attenuated by siRNA-mediated BIK downregulation, implicating a role for this BH3 protein in mediating toxicity. Furthermore, in cell lines with low IC 50 concentrations, BIK was shown to be highly expressed in comparison to cell lines with low BIK expression (for example, SKOV3) with the exception of the non-small cell lung cancer cell line 1299 which was sensitive despite loss of BIK (Zhu et al., 2005b) . This is consistent with evidence showing that mouse embryo fibroblasts lacking BIK are refractory to bortezomib. Disruption of calcium homeostasis by bortezomib is consistent with its effect on BIK expression at the ER (Landowski et al., 2005) . Furthermore, caspase activation can be inhibited by the calcium uniporter ruthenium red and ru360, which blocks mitochondrial uptake of calcium released from the ER (Kirichok et al., 2004) .
BIK upregulation enhances sensitivity to TRAIL (Nikrad et al., 2005; Zhu et al., 2005a; Nencioni et al., 2005b) . This effect is associated with upregulation of TRAIL receptor DR5, but with no evidence of upregulation of FLICE inhibitory protein (Zhu et al., 2005a) . Interestingly, inhibition of JNK signaling by SP600125, which is activated by bortezomib, abrogates the increase in DR5 expression but without attenuating synergy with TRAIL. Conversely, downregulation of BIK inhibits TRAIL sensitization, suggesting that it is BIK expression and not DR5 upregulation that is responsible for this observed synergy (Zhu et al., 2005a) .
BCL-2, BCL-X L A1 and BCL-W regulation by Bortezomib
BCL-2 and BCL-X L are multidomain antiapoptotic proteins that localize predominantly to the mitochondrial outer membrane, where they can interact with BH3-only proteins (Del Gaizo Moore et al., 2007) and/or BAX/BAK. The mechanism underlying inhibition of BAX/BAK by antiapoptotic BCL-2 family members remains controversial. Recent evidence suggests that antiapoptotic proteins can primarily prevent access of BAX/BAK to their canonical activators BID and BIM, that is, as a sequestration sink from which they are released by sensitizer BH3s (Kim et al., 2006) . Another model (Willis et al., 2007) suggests that BAX/BAK are constitutively engaged and restrained by their cognate antiapoptotic guardians, and that BID and BIM simply dissociate these interactions when free to do so. Although some studies have demonstrated downregulation of BCL-2 (Fahy et al., 2005) following bortezomib, this has not been consistently observed. BCL-X L is transcriptionally regulated by NF-kB; however, inhibition of IkB proteasomal degradation has not been demonstrated to be associated consistently with downregulation of BCL-X L . The mitochondrial antiapoptosis BCL-2 family member A1 is downregulated by bortezomib in hepatic stellate cells by a mechanism that involves inhibition of NF-kB (Anan et al., 2006) ; accordingly, the proteasome inhibitor MG132 and the specific IkBa inhibitor BAY 11-7082, can downregulate A1 in these cells and induce apoptosis. In this model, A1 siRNA is sufficient to induce cell death. BCL-W, which is a cytosolic antiapoptotic protein that undergoes translocation to the OMM, does not appear to alter its expression following treatment with bortezomib (Duechler et al., 2005) .
Optimization of BCL-2 family regulation by bortezomib BAX and BAK double knockout studies have confirmed an essential role for these multidomain proapoptotics in mediating bortezomib toxicity (Chauhan et al., 2005) . NPI-0052, a novel orally bioavailable proteasome inhibitor targets all three 20S proteasome activities (with more efficient CT-L and T-L inhibition compared to bortezomib). It has been reported to induce apoptosis by a mechanism that is independent of BAX and BAK expression, but relies on caspase 8 activation, and is relatively less sensitive to BCL-2 (Chauhan et al., 2005) . Absence of detectable BAX or BAK expression in vivo could be associated with potential for bortezomib resistance, and explain the lack of observed synergy with taxanes in the clinic (Mori et al., 2004) . Demonstration of synergistic interaction between NPI-0052 and bortezomib (Chauhan et al., 2005) suggests one strategy for enhancing clinical efficacy of bortezomib, perhaps in the drug-resistant setting.
Sensitizer BH3-type BAX/BAK activation has been exploited pharmacologically by small molecules with high affinity for antiapoptotic BCL-2 proteins (Oltersdorf et al., 2005; Certo et al., 2006) . BH3 mimetics such as ABT-737 and GX15-070, which are now entering the clinic, exhibit single-agent efficacy in some malignancies such as small cell lung cancer, leukaemia and neuroblastoma via release of endogenous activator BH3s from antiapoptotic BCL-2s at the OMM leading to BAX and BAK activation. MCL-1 expression has been identified as a resistance biomarker for ABT737, a BAD-like BH3 mimetic with affinity for BCL-2, BCL-X L and BCL-W (Oltersdorf et al., 2005; Konopleva et al., 2006; Lin et al., 2006; van Delft et al., 2006; Chen et al., 2007; Tahir et al., 2007) . The MCL-1 antagonism mediated by NOXA upregulation by bortezomib suggests that ABT737 and bortezomib may be a rational combination. Reports of synergy between the BH3 mimetic HA14-1 or the MCL-1 targeting mimetic GX15-070 and bortezomib support this hypothesis and warrant clinical evaluation (Campas et al., 2006; PerezGalan et al., 2007; Witters et al., 2007) . TRAIL receptor agonists are also entering the clinic; based on promising synergistic data in the preclinical setting (Johnson et al., 2003; Zhu et al., 2005a; Kabore et al., 2006) , the interaction between tBID and BIM-driven BAX and BAK activation could translate into promising clinical activity.
Concluding remarks
Emerging evidence now supports a critical role for upregulation and activation of BH3-only proteins in mediating the proapoptotic action of bortezomib. As such, this knowledge can underpin translational research linked to clinical trials to understand better the molecular determinants of sensitivity and resistance in the clinical setting, while in addition, suggesting new, rational combination strategies for treatment, with potential to improve outcome in patients with cancer.
